COMBINED COSTIMULATION BLOCKADE PLUS RAPAMYCIN BUT NOT CYCLOSPORINE PRODUCES PERMANENT ENGRAFTMENT1

Y Li, XX Zheng, XC Li, MS Zand, TB Strom - Transplantation, 1998 - journals.lww.com
Y Li, XX Zheng, XC Li, MS Zand, TB Strom
Transplantation, 1998journals.lww.com
Background. Combined treatment of allograft recipients with anti-CD40 ligand and CTLA-4Ig
(costimulation blockade) is a powerful promising albeit not consistently tolerizing therapy. It
would be desirable to use an effective conventional immunosuppressive regimen in low
doses or for a short course as an adjunct; however, cyclosporine treatment drastically blunts
the ability of costimulation blockade to produce long-term engraftment. Methods. Short
courses of cyclosporine or rapamycin were compared as adjuncts to costimulation blockade …
Abstract
Background.
Combined treatment of allograft recipients with anti-CD40 ligand and CTLA-4Ig (costimulation blockade) is a powerful promising albeit not consistently tolerizing therapy. It would be desirable to use an effective conventional immunosuppressive regimen in low doses or for a short course as an adjunct; however, cyclosporine treatment drastically blunts the ability of costimulation blockade to produce long-term engraftment.
Methods.
Short courses of cyclosporine or rapamycin were compared as adjuncts to costimulation blockade in the murine BALB/c to C3H/He heterotopic cardiac allograft model.
Results.
Although cyclosporine therapy blocked the capacity of costimulation blockade to produce permanent engraftment, combined rapamycin and costimulation blockade treatment produced permanent engraftment.
Conclusion.
A theoretical basis for the differing effects of cyclosporine and rapamycin upon the outcome of costimulation blockade is forwarded. Combined use of costimulation blockade and rapamycin may provide a means to bring costimulation blockade into the clinic.
Lippincott Williams & Wilkins